NVO: 6-K company filing

6-K 1 f6k_090726.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 7, 2026 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 07 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027. Since the announcement 31 August, the following transactions have been made: Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 16,220,000 4,907,673,815 31 August 2026 210,000 291.92 61,302,771 1 September 2026 215,000 293.94 63,196,785 2 September 2026 215,000 297.42 63,945,131 3 September 2026 215,000 305.35 65,649,697 4 September 2026 200,000 300.03 60,006,094 Accumulated under the programme 17,275,000 5,221,774,293 The details f